Merck Announces Fourth-Quarter 2024 Dividend

Rhea-AI Summary

Merck (NYSE: MRK) has announced its quarterly dividend for the fourth quarter of 2024. The Board of Directors has declared a dividend of $0.77 per share of the company's common stock. This dividend will be paid on October 7, 2024, to shareholders who are on record at the close of business on September 16, 2024. Merck, also known as MSD outside of the United States and Canada, continues to provide returns to its shareholders through consistent dividend payments, demonstrating the company's financial stability and commitment to investor value.

Positive

• Consistent dividend payment of $0.77 per share
• Demonstrates financial stability and commitment to shareholder returns

Negative

• None.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the fourth quarter of 2024. Payment will be made on Oct. 7, 2024, to shareholders of record at the close of business on Sept. 16, 2024.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723284638/en/

Media Contacts:

Robert Josephson

(203) 914-2372

robert.josephson@merck.com

Michael Levey

(215) 872-1462

michael.levey@merck.com

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

peter.dannenbaum@merck.com

Steven Graziano

(732) 594-1583

steven.graziano@merck.com

Source: Merck & Co., Inc.

FAQ

What is Merck's (MRK) dividend amount for Q4 2024?

Merck (MRK) has declared a quarterly dividend of $0.77 per share for the fourth quarter of 2024.

When will Merck (MRK) pay its Q4 2024 dividend?

Merck (MRK) will pay its fourth-quarter 2024 dividend on October 7, 2024.

What is the record date for Merck's (MRK) Q4 2024 dividend?

The record date for Merck's (MRK) fourth-quarter 2024 dividend is September 16, 2024.

How often does Merck (MRK) pay dividends?

Based on the announcement of a quarterly dividend, Merck (MRK) typically pays dividends four times a year.